GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET

7.1 GLOBAL GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)

8.1 GLOBAL GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

8.2 GLOBAL GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

9.1 GLOBAL GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

9.2 GLOBAL GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

10.1 GLOBAL GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)

10.2 GLOBAL GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)

11.1 NORTH AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

11.2 NORTH AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

11.3 NORTH AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

11.4 NORTH AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

11.5 NORTH AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

11.6 NORTH AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

12.1 EUROPE GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

12.2 EUROPE GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

12.3 EUROPE GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

12.4 EUROPE GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

12.5 EUROPE GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

12.6 EUROPE GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

13.1 ASIA PACIFIC GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

13.2 ASIA PACIFIC GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

13.3 ASIA PACIFIC GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

13.4 ASIA PACIFIC GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

13.5 ASIA PACIFIC GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

13.6 ASIA PACIFIC GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

14.1 LATIN AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>

14.2 LATIN AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

14.3 LATIN AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

14.4 LATIN AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

14.5 LATIN AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

14.6 LATIN AMERICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA GENERIC AND BIOSIMILAR PHARMACEUTICALS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>

16.1 Roche

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Amgen

16.3 AbbVie

16.4 Sanofi-Aventis

16.5 Johnson & Johnson

16.6 Pfizer

16.7 Novo Nordisk

16.8 Eli Lilly

16.9 Novartis

16.10 Merck

16.11 3sbio

16.12 Changchun High Tech

16.13 CP Guojian

16.14 Biotech

16.15 Gelgen

16.16 Innovent

16.17 Dong Bao

16.18 Ganlee

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER